Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
In This Article:
-
Alera Pharma, Inc. is a newly formed C-Corp wholly owned by Lobe Sciences, Ltd.
-
Mr. Rick Goulburn is appointed as the Chief Executive Officer of Alera Pharma, Inc.
-
Dr. Frederick D. Sancilio has been appointed as Chairman of the Alera Pharma, Inc. while Dr. Harry Jacobson, Mr. Wesley Ramjeet, and Mr. Goulburn are appointed as Members of the Board.
-
Lobe Sciences Australia Pty Ltd. will become a subsidiary of Alera Pharma, Inc. and Mr. Ilan Hayman will become a member of the executive management team of Alera Pharma.
-
Intellectual property rights associated with Lobe’s lead compound, Psilocin Mucate, will move to Alera Pharma.
-
Notice of Allowance received from US PTO for US Patent Application Serial No. 18/411,576.
VANCOUVER, British Columbia, August 16, 2024--(BUSINESS WIRE)--Lobe Sciences, Ltd ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with unmet medical needs, today announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma, Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate.
Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera.
Dr. Sancilio, Chairman and CEO of Lobe Sciences said, "At present, Lobe Sciences has a complex corporate structure. By establishing Alera Pharma, we are simplifying the operations of the Company into just three entities. Lobe Sciences, Ltd will provide common services to the two operating subsidiaries - Alera and Altemia, LLC. The creation of two separate operating companies will allow each entity to create value within their respective therapeutic areas; neurology and hematology."
The Company also announces the receipt from the US PTO of a Notice of Allowance for its U.S. Patent Application Serial No. 18/411,576.
About Lobe Sciences Ltd.
Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia?, a medical food designed to meet the needs of sickle cell patients globally.